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In 1993, the National Institutes of Health (NIH) Revitalization Act was passed by United States
Congress and signed into law by President Clinton. The Act called for the NIH to require that
all federally funded clinical research prioritize the inclusion of women and minorities and that
research participant characteristics be disclosed in research documentation [1]. When pivotal
NIH-funded studies included large proportions of women by design, they made important,
Summary Points
• Health disparities persist across race/ethnicity for the majority of Healthy People 2010
health indicators.
• Most physicians and scientists are informed by research extrapolated from a largely
homogenous population, usually white and male.
• A growing proportion of Americans are not fully benefiting from clinical and biomedi-
cal advances since racial and ethnic minorities make up nearly 40% of the United States
population.
• Ignoring the racial/ethnic diversity of the US population is a missed scientific opportu-
nity to fully understand the factors that lead to disease or health.
• US biomedical research and study populations must better reflect the country’s chang-
ing demographics. Adequate representation of diverse populations in scientific
research is imperative as a matter of social justice, economics, and science.
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clinically relevant scientific contributions by identifying sex-specific differences in symptoms,
pathologies, and treatment response [2–4]. In continuation of this effort, the NIH announced
new measures to enhance gender equity [5]. Herein, we evaluate the impact of the Revitaliza-
tion Act’s other stated aim: diversifying study populations by race/ethnicity. We also make sug-
gestions on what we believe will bolster the Revitalization Act’s effect in shaping clinical and
biomedical research and thereby provide guidance for President Obama’s new Precision Medi-
cine Initiative (PMI) [6].
Disease Pattern, Clinical Presentation, and Therapeutic Response
Can Vary Dramatically by Race/Ethnicity and Ancestral
Background
Race is a social construct rooted in cultural identity and shaped by historic and current events,
which influence an individual’s behavior and place of residence. Genetic variation correlates
with self-identified race [7], and this genetic variation also correlates with clinical presentation
and therapeutic response. Thus, while not every study needs to examine racial differences or
include all racial/ethnic groups, we feel that the group(s) included should be representative of
their larger population(s) such that including an adequate proportion of racially/ethnically
diverse groups in clinical and biomedical research can provide meaningful opportunities to
examine the complex relationship of ancestral influences, environmental exposures, and social
factors. In turn, understanding the interaction between the social and environmental milieu
with an individual’s genomic profile and genetic ancestry can extend our understanding of dis-
ease pathology and expand therapeutic options for everyone [8]. For example, up to 75% of
Pacific Islanders are unable to convert the antiplatelet drug clopidogrel into its active form and
are at higher risk for adverse outcomes following angioplasty [9,10]. Other examples are listed
in Table 1.
Table 1. Insights from studies conducted in diverse race/ethnic groups.
Trait Findings
Breast cancer Differences in Native American ancestry at the estrogen receptor locus led to
discovery of a genetic variant that was protective against breast cancer in Latinas
[11].
Heart failure A post-hoc analysis of clinical trials of fixed-dose combination of hydralazine and
isosorbide dinitrate suggested that black, but not white patients had a significant
reduction in mortality compared to placebo [12].
Increased preterm
birth rate
Exposures to endocrine disrupting chemicals such as bisphenol-A (BPA) are
more common among minorities who live in low socioeconomic strata. BPA
causes epigenetic alterations of the germ line resulting in increased preterm birth
rate; these alterations can pass down to future generations [13].
Stevens-Johnson
syndrome
The risk of carbamazepime-induced Stevens-Johnson syndrome due to
HLA-B*1502 is highest in populations of Southeast Asian and East Asian
ancestry [14].
Kidney disease Genetic variants of APOL1 have been associated with kidney disease in
individuals of African ancestry whose ancestors lived in regions of Africa endemic
with trypanosomiasis; these renal risk variants are largely absent in individuals of
European or Asian ancestry [15].
Response to efavirenz Blood levels and treatment response to this antiretroviral drug are influenced by
individual ancestral make up, which can be accounted for by polymorphisms of
cytochrome 2B6 and genetically defined ancestry [16,17].
doi:10.1371/journal.pmed.1001918.t001
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Past Research Has Under-Studied Minorities
The US has been regarded as a “global lead” and “exemplar” in biomedical and clinical health
research since the end of the Cold War [18]. Yet, few US biomedical studies focus recruitment
efforts on attaining adequate minority representation, nor do they focus their research atten-
tion to factors most relevant to minority health [19]. Since the passage of Revitalization Act in
1993, less than 2% of more than 10,000 cancer clinical trials funded by the National Cancer
Institute included enough minority participants to meet the NIH’s own criteria and goals [20].
Moreover, less than 5% of NIH-funded respiratory research reported inclusion of racial/ethnic
minorities [21]. Minority enrollment in cancer clinical trials remains inadequate despite strik-
ing racial/ethnic disparities in cancer incidence and mortality [22,23]. Similar incongruities
between disease burden and representation in biomedical research exist for cardiovascular dis-
eases and diabetes [24,25]. These disparities have economic consequences: eliminating racial/
ethnic health disparities would have reduced total medical costs during 2003–2006 by more
than $1.2 trillion [26]. Some NIH reviewers have argued that the inclusion of diverse groups
will increase the financial costs of clinical and biomedical research. However, it is generally
agreed upon that the long-term financial benefits outweigh short-term expenses [27]. The
social, biomedical, and economic costs of inaction are ameliorated by a new appreciation for
the clinical and biomedical benefits achieved through precision medicine when applied to all
populations [6]. The proportion of taxpayers who have not gained optimal benefit from scien-
tific discoveries they are funding continues to grow with the changing US demographics.
Therefore, ensuring that diverse populations are adequately included in scientific research is
imperative not only in terms of scientific integrity and fiduciary responsibility but also as a
matter of social justice.
Barriers to Diversify Research Need Concerted Attention
While US minorities may be as willing to participate in health research as non-Hispanic whites
[28], barriers to participation among minority populations must be addressed and will require
buy-in from stakeholders: funders, academic institutions, investigators, and potential research
participants [29]. Minority populations often have limited access to specialty care centers that
serve as referral sources for clinical studies, resulting in a lack of an effective referral base [30].
Other barriers include, but are not limited to, fears of exploitation in medical research [31],
financial constraints [32], competing demands of time, lack of access to information and com-
prehension about research, unique cultural and linguistic differences, fears of unintended out-
comes, stigmatization, and health care discrimination [31].
Highly feasible changes can increase minority participation despite the challenges described.
Ideally, investigators would reflect the communities being studied. Given the tremendous dis-
parities in our biomedical workforce, we must seek out other realistic solutions. For example,
some participants prefer studies that include research staff who share their same culture and
with whom they can communicate in their own language [31]. Potential contributors are also
more likely to partake when recruited by research staff they personally know or with whom
they identify [33,34]. Town hall meetings and study newsletters can be adapted to the language
and reading level requirements of target groups; these can describe how collected data will be
used, ensuring transparency and allaying fears stemming from lack of information [29]. Chal-
lenges of transportation, childcare, work hour considerations, and meals can be addressed via
payment, travel support, flexible recruitment hours and locations, provision of food during
study visits, and positioning study sites in areas with diverse residents. To compensate for the
limited internal referral base, tertiary care centers can partner with community health care pro-
viders. Targeted advertising (e.g., on public transportation) can reach potential participants at
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a moderate cost. Nonetheless, outreach and external partnerships introduce costs and effort
that can raise recruitment budgets. The Revitalization Act specifically prohibits cost consider-
ations from being a reason to exclude minorities, and NIH study sections are instructed to dis-
regard budgetary requests in evaluating a project’s scientific merit. However, our experience in
grant reviewing has been that in practice, the size of budgetary requests can bias reviewers.
Grant applicants, in turn, react by submitting proposals with inadequate budgets to recruit
minority participants so as not to “raise eyebrows” of reviewers.
Minorities would likely to be as willing to be involved in research as whites if problems of
diversity could be better addressed. Some of these problems may stem from issues within the
research community and its own profound diversity gap. Minority physicians and scientists
are more likely to conduct research in minority populations and are often best suited to gain
the trust of minority communities, but they are also significantly underrepresented in medical
and scientific communities [35]. For example, blacks or African Americans and Hispanics,
respectively, represented only 4.3% and 7.2% of doctorate degree awardees in biomedical sci-
ences in 2013, although they represented 13.9% and 17.2% of the US population during the
same period [36]. Moreover, less than 2% of NIH principal investigators on research project
grants are black [37], a proportion much lower than in the general US population (10.2%) [38].
Similar disparities were observed for Latinos (3.4% versus 12.5%), American Indians and
Alaska Natives (0.4% versus 0.7%), and Native Hawaiians and other Pacific Islanders (1.2%
versus 10.2%).
To further complicate the picture, an NIH study of research grant awards found that the
proportion of applications funded was 13% lower for blacks or African Americans and 4%
lower for Asians than among whites [39]. According to demographic information provided by
the NIH’s Office of Extramural Research under the Freedom of Information Act, the award
rate for R01 or equivalent grants has been consistently lower among non-white applicants
(Pacific Islander, Native Hawaiian, African American, American Indian, and Asian) than
white applicants (42.1% versus 48.6% in 1985 and 19.3% versus 23.3% in 2013) [40].
Contributors to funding disparities arise throughout the research application review process
[41]. The NIH has commented on reviewer bias [42], acknowledging that the probability of
funding after peer review does not differ by race, but that minority investigators tend to receive
lower priority scores from peer review, indicating that the review process is biased against
applications from minority investigators. The relative absence of minority participants
throughout the research application evaluation process may contribute to this problem, since
underrepresented minorities comprised 10% of NIH study section reviewers in 2000 and only
10.9% in 2013 [40]. Increasing minority representation within the research community could
in itself promote better science. Diverse research teams are more likely to have diverse ideas
[43], which may explain why manuscripts authored by multi-ethnic research teams are more
likely to be cited than publications authored by authors of the same ethnicity [44]. However,
since study section members are drawn from the pool of successfully funded researchers, fund-
ing disparities have a self-perpetuating effect [45] and functionally eliminate scientists best
suited to respond to the call to action we describe.
How Can the NIH (Re)catalyze Diversity in Research?
The Revitalization Act intended to re-catalyze diversity in biomedical research by increasing
minority representation. President Obama’s Precision Medicine Initiative plans to enroll a
cohort of 1 million or more Americans that will provide the platform for expanding our knowl-
edge and benefit the nation for many years to come. It is time to heed the President’s call to
action, given the changing US demographics. The NIH should be empowered to set and
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enforce recruitment of diverse research populations as the default and require scientific justifi-
cation for limited or selected study population enrollment, as they have just created policies to
do for sex balance [5]. Other US government agencies (e.g., Centers for Disease Control and
Prevention, Food and Drug Administration, Agency for Healthcare Research and Quality,
Patient-Centered Outcomes Research Institute, Department of Defense) should be similarly
empowered. Recruitment approaches should be formally included as criteria for scientific
merit scoring, rather than the current application of such criteria after scoring.
In this vein, the NIH should include race/ethnicity as a criterion for assigning priority scores
to ensure that well-characterized cohorts and clinical trials not only answer questions relevant
to the growing diversity of the US population but are also appropriately statistically powered.
The same techniques for monitoring sex/gender inclusion [5] should be used to explicitly
review minority accruals over the course of the award, and adjust funding levels accordingly.
We believe this would prompt researchers of all racial/ethnic and cultural backgrounds to
incorporate understudied populations in their research studies.
To their credit, the NIH is actively addressing many of the issues we have mentioned. Fol-
lowing President Obama’s PMI announcement during his 2015 State of the Union address, the
NIH has actively solicited feedback [46] to help guide creation of a diverse research cohort of 1
million or more Americans [47]. The NIH has since hosted several workshops to develop a
vision for building the national PMI cohort, and maximizing cohort diversity (across socioeco-
nomic standing, geography, sexual orientation, education, and age, in addition to race/ethnic-
ity) has been an ongoing topic at these workshops [48]. In particular, participant and public
engagement, diversity and inclusion, and health disparities considerations for the development
of a national research cohort were among the topics discussed at a workshop dedicated to par-
ticipant engagement and health equity [49].
We applaud and encourage the NIH’s focus on diversifying the makeup of the forthcoming
PMI cohort. To build on these efforts, an administrative supplement for currently funded
research to investigate racial/ethnic differences in health and therapeutics should be created,
similar to efforts by the Office of Research on Women’s Health to promote discovery of sex dif-
ferences [50]. This supplement would be hypothesis-generating and show the NIH’s commit-
ment to diversify study populations throughout all Institutes. The NIH should also incentivize
collaboration amongst groups with similar approaches and data elements so that adequately
powered analyses can examine racial/ethnic differences.
Applications from minority-serving institutions should be judged on their capacity to con-
duct research rather than relying on the institutions’ research track records. In our experience,
applications from institutions with strong community ties are better equipped to enroll and
retain subjects in clinical and biomedical research. The importance and novelty of studies
focused primarily or solely on minority populations should be recognized for their validity and
worth, as these may be the only studies to recruit sufficient minority participants to determine
whether research findings can be generalized to these populations.
Given the systemic bias against minority scientists, the solution does not lie in simply
increasing the number of competitive applicants. To this end, the NIH is actively funding
investigations to understand and eliminate discrepancies for minority investigators in the peer
review process [51]. In September 2014, the NIH announced [52] winners of two competitions
on increasing the fairness and impartiality of the scientific review process and for novel meth-
ods of identifying bias. A program assessing the complete anonymization of grant applications
is also being piloted [53]. These efforts are part of a larger campaign to identify and root out
unconscious bias in peer review [41,51]. The NIH must act on these data to ensure a just and
fair voice for all stakeholders.
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NIH proposals passing scientific peer review are forwarded to a second level of review, con-
ducted by Institute and Center (IC) National Advisory Councils or Boards (henceforth referred
to as “Councils”). NIH Councils make funding decisions based on the priority score and the
priorities of the IC, which have varying levels of discretionary funds. A reasonable way to fund
meritorious applications that reflect the diversity priorities of the ICs is to use the discretion of
the Councils. Other NIH efforts to increase support for the diversity pipeline (e.g., NIH’s Build-
ing Infrastructure Leading to Diversity (BUILD) Initiative [54]) and for diversity-related scien-
tific initiatives are commendable, but in the absence of strong changes throughout the review
process, research will continue to suffer.
Inclusive Research Needs the Support of the Entire Country
Efforts by the NIH and other agencies to address disparities in research priorities will have lim-
ited impact unless broader themes of political and economic inequality are addressed. The
most important changes in our approach to science will only come when we consider inclusion
and diversity important by default—not just in biomedical science, but in all aspects of society.
Homogeneity in study populations will cease when racial/ethnic and socioeconomic diversity
are considered socially desirable and social norms [55], be it in study populations, academic
faculty, NIH study sections, or boardrooms and classrooms.
We have suggested a number of measures for the NIH to build upon the Revitalization Act.
Despite the Act’s stipulation that cost not be used as justification for failure to enroll diverse
populations, no discussion of new mandates for NIH-funded research can take place without
addressing the crisis of declining inflation-adjusted NIH budgets. Society and patients will ben-
efit when the NIH exercises the full scope of power provided under the 1993 Act: a call for the
inclusion of historically under-represented communities in clinical research. The NIH alone
will not be able to correct the disparities or inequities of the health care system, but it can send
a powerful message that may promote changes in our health care and health science systems.
There must be a collective will to prioritize diversifying our study populations, rallied by out-
reach to the lay community to educate voters who can exercise their franchise to their own best
health care interests.
Fulfilling the promise of the Revitalization Act does not pit a future of precision medicine
and the advancement of science against the realization of social justice for under-represented
communities. Rather, the choice to study diverse populations is itself a promising path toward
sound science. By reprioritizing our approach to clinical research and recruitment, we may
accomplish an even greater goal: to usher in a new era of scientific discovery and health pros-
perity for all citizens of the world.
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